1. Remimazolam anesthesia for cardiac surgery with cardiopulmonary bypass: a case report
- Author
-
Michiaki Yamakage, Kota Saito, Sho Ohno, Makishi Maeda, and Naoyuki Hirata
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Case Report ,law.invention ,lcsh:RD78.3-87.3 ,03 medical and health sciences ,0302 clinical medicine ,030202 anesthesiology ,law ,Anesthesiology ,medicine ,Cardiopulmonary bypass ,Remimazolam ,Mitral valve repair ,business.industry ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,030208 emergency & critical care medicine ,Perioperative ,lcsh:RC86-88.9 ,Cardiac surgery ,Anesthesiology and Pain Medicine ,lcsh:Anesthesiology ,Bispectral index ,Anesthesia ,Propofol ,business ,medicine.drug - Abstract
Background Remimazolam has less cardiovascular depressant effects than propofol in non-cardiac surgical patients. However, the efficacy and safety of remimazolam in cardiac surgery with cardiopulmonary bypass (CPB) have not been reported. We present a case of successful anesthetic management using remimazolam in cardiac surgery with CPB. Case presentation A 76-year-old female was scheduled for mitral valve repair, tricuspid annuloplasty, maze procedure, and left atrial appendage closure. We used remimazolam in induction (6.0 mg/kg/h) and maintenance (0.6–1.0 mg/kg/h) of general anesthesia, and the bispectral index value was maintained in the range of 36 to 48 including the period of CPB. Hemodynamics, mixed venous oxygen saturation, and bilateral regional cerebral oxygen saturation were maintained within acceptable ranges. There was no intraoperative awareness/recall or serious complications associated with remimazolam throughout the perioperative period. Conclusions Remimazolam can be used the same as other existing anesthetics in cardiac surgery with CPB.
- Published
- 2021